Vividion Therapeutics, Inc, a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. Vividion is a wholly owned and independently operating subsidiary of Bayer AG.
The new facility will support the continued development of Vividion’s R&D capabilities, including a significant increase in the company’s chemoproteomics screening capacity. More than half of the expansion will be dedicated to state-of-the-art research labs where Vividion will continue advancing its expansive portfolio of clinical and preclinical programs as well as future programs that emerge from the company’s discovery efforts. The new facility will accommodate strategic growth capabilities and enable the company to continue to attract and retain top life sciences experts in San Diego, a rapidly growing hub for biotech innovation.
“Vividion has entered an exciting new stage in the company’s development, with multiple programs in clinical trials, a rich discovery portfolio and expansive platform screening efforts focused on bringing more previously undrugged disease-causing targets within the reach of small molecule therapeutics. Our new R&D center and headquarters will provide the infrastructure to execute our strategic vision and continue to lead the way in applying chemoproteomics and covalent chemistry to create first-in-class medicines for patients in need,” said Aleksandra Rizo, M.D., Ph.D., Chief Executive Officer of Vividion. “Vividion’s culture of innovation has always been driven by outstanding people working collaboratively in a dynamic and supportive environment. We’re looking forward to continuing and building on that tradition in our new state-of-the-art home.”
“Vividion is a key component of Bayer’s innovation strategy and its focus on bringing first-in-class medicines to market to address longstanding unmet medical needs,” said Stefan Oelrich, Member of the Board of Management of Bayer AG and President Pharmaceuticals at Bayer. “This new facility will support our strategic growth opportunities to enable the company to capitalize on the rich array of drug discovery and clinical development opportunities afforded by its pioneering chemoproteomics platform.”
Comments powered by CComment